weight loss, obesity drugs
Compound versions of weight loss drugs will no longer be available, FDA rules
The FDA says state-licensed compounding pharmacies must immediately stop making compound versions of GLP-1 drugs. Larger, national licensed facilities making compound versions of Zepbound have until March 19 to stop, according to the FDA.
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Stanford Medicine researchers have identified a naturally occurring molecule that mimics the appetite-suppressing effects of ...
Drugs like Ozempic have a positive impact on weight loss, though only for a short period, with long-term health implications ...
Novo Nordisk is lowering the price of its weight-loss drug Wegovy to $499 per month for some patients paying out of pocket.
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...
We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...
The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all ...
Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback